BIOMUNE SYSTEMS INC
10QSB, EX-27, 2000-08-21
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BIOMUNE SYSTEMS INC, 10QSB, 2000-08-21
Next: REAL ESTATE ASSOCIATES LTD VI, 10-Q, 2000-08-21



<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               SEP-30-2000
<PERIOD-START>                  APR-01-2000
<PERIOD-END>                    JUN-30-2000
<CASH>                                          29,928
<SECURITIES>                                   864,434
<RECEIVABLES>                                  113,899
<ALLOWANCES>                                   (13,653)
<INVENTORY>                                    215,452
<CURRENT-ASSETS>                               492,405
<PP&E>                                         175,427
<DEPRECIATION>                                (103,145)
<TOTAL-ASSETS>                               2,271,959
<CURRENT-LIABILITIES>                          506,818
<BONDS>                                              0
                                0
                                    192,642
<COMMON>                                           860
<OTHER-SE>                                   1,571,639
<TOTAL-LIABILITY-AND-EQUITY>                 2,271,959
<SALES>                                        133,408
<TOTAL-REVENUES>                               133,408
<CGS>                                           84,025
<TOTAL-COSTS>                                   84,025
<OTHER-EXPENSES>                            (1,569,963)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                             (1,688,827)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (1,688,827)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (1,688,827)
<EPS-BASIC>                                    (0.20)
<EPS-DILUTED>                                    (0.20)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission